Stockscreener 앱 받기
38.27
2.15%
-0.84
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? - Nasdaq
Legal & General Group Plc Has $3.85 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts - Yahoo Finance
Crispr Therapeutics Benefits From Diverse Gene Editing Portfolio; Positive Long-Term Outlook - Morningstar
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030 - 24/7 Wall St.
Capital International Sarl Has $7.36 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Wells Fargo & Company MN Has $8.66 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - MSN
Leerink Partnrs Issues Negative Estimate for CRSP Earnings - MarketBeat
‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital - Yahoo Finance
Capital International Investors Purchases 816,789 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Jump Financial LLC Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Advisory Services Network LLC Sells 7,629 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline - TipRanks
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Geode Capital Management LLC Has $39.41 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Should You Sell? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Reynders McVeigh Capital Management LLC - MarketBeat
CRISPR Therapeutics stock pops following disclosure of RFK Jr. investment - MSN
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
BofA Adjusts Price Target on CRISPR Therapeutics to $80 From $86, Keeps Buy Rating - marketscreener.com
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities - The Globe and Mail
BofA Adjusts Price Target for Crispr Therapeutics (CRSP) to $80 | CRSP Stock News - GuruFocus
Vanguard Group Inc. Acquires 10,579 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week - Yahoo Finance
How To Trade (CRSP) - news.stocktradersdaily.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Consensus Target Price from Analysts - MarketBeat
Gene Therapy Market Anticipated to Witness 20% CAGR Growth by 2029: Top Key Players like Novartis, Roche, CRISPR Therapeutics - PharmiWeb.com
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
California Public Employees Retirement System Trims Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
443,536 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Bought by Norges Bank - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 12-Month LowTime to Sell? - MarketBeat
LPL Financial LLC Buys 42,232 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics: Is This Biotech Surge Here to Stay? - timothysykes.com
First Week of May 30th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
Goldman Sachs maintains Neutral on CRISPR Therapeutics stock By Investing.com - Investing.com South Africa
Goldman Sachs maintains Neutral on CRISPR Therapeutics stock - Investing.com
47,840 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Bought by ExodusPoint Capital Management LP - MarketBeat
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
0.24%
36.06%
자본화:
|
볼륨(24시간):